Axsome Therapeutics Receives Pre-IND Guidance from FDA for AXS-05 for Agitation in Patients with Alzheimer’s Disease
Phase 2/3 Trial Planned in Agitation in Alzheimer’s Disease IND Submission Expected in 2016 NEW YORK, April 20, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the …